青蒿琥酯-阿莫地喹联合疗法治疗加蓬幼儿恶性疟
Artesunate--amodiaquine combination therapy for falciparum malaria in young Gabonese children.
作者信息
Oyakhirome Sunny, Pötschke Marc, Schwarz Norbert G, Dörnemann Jenny, Laengin Matthias, Salazar Carmen Ospina, Lell Bertrand, Kun Jürgen F J, Kremsner Peter G, Grobusch Martin P
机构信息
Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon.
出版信息
Malar J. 2007 Mar 12;6:29. doi: 10.1186/1475-2875-6-29.
BACKGROUND
Artesunate-amodiaquine combination for the treatment of childhood malaria is one of the artemisinin combination therapies (ACTs) recommended by National authorities in many African countries today. Effectiveness data on this combination in young children is scarce.
METHODS
The effectiveness of three daily doses of artesunate plus amodiaquine combination given unsupervised (n = 32), compared with the efficacy when given under full supervision (n = 29) to children with falciparum malaria were assessed in an unrandomized study.
RESULTS
61 patients analysed revealed a PCR-corrected day-28 cure rate of 86 % (25 of 29 patients; CI 69-95 %) in the supervised group and 63 % (20 of 32 patients; CI 45-77 %) in the unsupervised group. The difference in outcome between both groups was statistically significant (p = 0.04). No severe adverse events were reported.
CONCLUSION
The effectiveness of this short course regimen in young children with falciparum malaria could be augmented by increased adherence and improved formulation.
背景
青蒿琥酯-阿莫地喹联合用药治疗儿童疟疾是当今许多非洲国家国家当局推荐的青蒿素联合疗法（ACTs）之一。关于这种联合用药在幼儿中的有效性数据很少。
方法
在一项非随机研究中，评估了对32名未接受监督的儿童每日三次给予青蒿琥酯加阿莫地喹联合用药的有效性，并与29名接受全程监督的儿童的疗效进行了比较。
结果
对61名患者的分析显示，在接受监督的组中，经PCR校正的第28天治愈率为86%（29名患者中的25名；CI 69-95%），在未接受监督的组中为63%（32名患者中的20名；CI 45-77%）。两组之间的结果差异具有统计学意义（p = 0.04）。未报告严重不良事件。
结论
增加依从性和改进配方可提高这种短程疗法对患恶性疟原虫疟疾幼儿的有效性。
Zotero 插件